(Total Views: 732)
Posted On: 06/08/2022 12:36:02 AM
Post# of 157705
Well said.
“this bodes well for leronlimab, as dostarlimab being a mab promotes other mabs. another mab with minimal side effects. a trend. plus a tiny group of 14 patients taken as quality data. cytodyn constantly criticized for too small trial sizes. our ASCO poster should be taken seriously also. enhertu praised for extended survival, as it should. leronlimab is extending survival also. by a lot. with no side effects. love that. “
“this bodes well for leronlimab, as dostarlimab being a mab promotes other mabs. another mab with minimal side effects. a trend. plus a tiny group of 14 patients taken as quality data. cytodyn constantly criticized for too small trial sizes. our ASCO poster should be taken seriously also. enhertu praised for extended survival, as it should. leronlimab is extending survival also. by a lot. with no side effects. love that. “
(4)
(0)
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
— Jeremiah 51:36
